Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amyvid Approval Delay Seems Likely; Questions On Utility Of Training, Plaque Detection Itself Remain

Executive Summary

It appears the training program for Amyvid may still need some work, but Eli Lilly & Co. remains confident the diagnostic will gain FDA approval.
Advertisement

Related Content

Amyvid Training Issues Lead To Complete Response Letter, Could Force More Trials
Can Amyvid Be An Important Alzheimer's Product Without An Alzheimer's Indication?
Can Amyvid Be An Important Alzheimer's Product Without An Alzheimer's Indication?
Lilly Loses Neuroscience Chief To Johnson & Johnson
Can Amyvid Be An Important Alzheimer's Product Without An Alzheimer's Indication?
Avid Amyvid Could Be Approved If Training Improves, Advisory Committee Says
Lilly/Avid Alzheimer's Diagnostic May Need To Broaden Target Population Before Advisory Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS053199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel